Drugs
Astex, a fragment-based drug discovery and development company, has achieved a significant milestone with the approval of its Investigational New Drug (IND) application for the clinical development of its proprietary cell cycle inhibitor, AT7519, for the treatment of cancer. This approval marks a major breakthrough for Astex, allowing the company
Drugs
Clinical trials for Onyvax-P, a new immunotherapy, have revealed encouraging results in delaying the progression of hormone-resistant prostate cancer (HRPC) in patients. A paper published in Clinical Cancer Research confirms that the treatment, administered to patients with rising PSA levels, demonstrated a statistically significant decrease in PSA velocity and a
Drugs
BioLineRx has signed in-license agreements to develop and commercialize two new therapeutic candidates, BL-2030 and BL-2040, for the treatment of prostate cancer and metabolic syndrome, respectively. The company has obtained a worldwide exclusive license for the development of both compounds from BioRap Technologies and Yeda Research and Development Company, Ltd.
Drugs
Researchers from INSERM U375, IRCAD have successfully developed a novel approach to killing pancreatic cancer cells using a modified Escherichia coli suicide gene. The study, published in the Journal of Gene Medicine, utilized a cell-specific gene delivery system to limit host toxicity. By harnessing the power of tumor marker promoters,
Drugs
Recent studies published in top immunology journals have provided significant insights into cancer vaccine development, highlighting the potential of new approaches to combat this disease. Researchers in Italy, the United States, and Germany have made strides in understanding the workings of cancer vaccines, including the use of dendritic cells and
Drugs
Research conducted at Gifu University in Japan suggests that the efficacy of certain chemotherapy treatments for gastric cancer may be linked to the status of the p53 gene. A study published in the International Journal of Oncology found that cancers with wild-type p53 may respond better to treatment with 5-fluorouracil
Drugs
Preclinical studies have identified the molecular pathways by which mda-7, the active component of INGN 241, induces growth arrest and programmed cell death (apoptosis) in cancer cells. Researchers at Introgen Therapeutics, Inc., and The University of Texas M. D. Anderson Cancer Center have found that MDA-7 protein binds to a
Drugs
Clinical trials led by researchers at the University of Texas, MD Anderson Cancer Center in Houston have shown that celecoxib, a selective cyclooxygenase-2 inhibitor, can be safely used concurrently with thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC). The study aimed to determine whether celecoxib could be safely
Drugs
In a special session at the American Society of Gene Therapy 8th Annual Meeting (ASGT), Introgen Therapeutics, Inc. (INGN) highlighted the progress of its investigational cancer therapies, Advexin(R) and INGN 225. These therapies are currently being evaluated in Phase 3 and Phase 2 trials, respectively. The session, titled "
Drugs
Recent research in the United States has made significant strides in gene transfer, focusing on developing new strategies for therapeutic gene expression. Studies have explored the use of bicistronic vectors, synthetic cyclodextrin-based constructs, and the Sleeping Beauty transposon system to improve gene transfer efficiency and long-term expression. These innovative approaches
Drugs
Advanced small cell lung cancer (SCLC) patients who received Introgen Therapeutics' investigational cancer vaccine, INGN 225, showed a significantly higher response rate to second-line chemotherapy compared to historical controls. The results of the phase II trial, presented at the 41st Annual Meeting of the American Society of Clinical Oncology
Drugs
Research in cancer vaccines has been gaining momentum, with studies in the United States, Australia, and France shedding light on innovative approaches to inducing tumor-specific immunity. By targeting surrogate tumor antigens, short peptide sequences, and self-reactive T cell receptors, scientists are developing effective strategies to combat cancer. These findings offer
